Table 6

Real-life cohort participants with a discrepancy between SARS-CoV-2 RT-PCR and dog response

ParticipantsDog responseRT-PCR (viral load)SymptomsTime between symptom onset and skin swab/between RT-PCR test and skin swab, daysAntibody test result (time between RT-PCR test and antibody test, days)CommentSARS-CoV-2 infection status (variant*, if available)
RL1NegativePositive (medium)AsymptomaticNA†/0Negative (81)Two additional negative PCR testsNegative (wild-type)‡
Muscle aches, headache, fever1/0Positive (57)Positive (alpha)
Asymptomatic−10/0Positive (56)Fever, cough, dyspnoea, headache 10 days before testsPostinfectious prolonged PCR positivity (wild-type)
RL4Positive (two dogs)NegativeAsymptomaticNA/0Negative (178)Negative scent dog test and PCR-test within 1 monthNegative
RL5Positive/Negative (two dogs)NegativeAsymptomaticNA/0Negative (97)Negative
RL6Positive (two dogs)NegativeChest pain, cough, tachycardia, fever1/0Negative (113)Second PCR test negative 4 days after initial testNegative
RL7PositiveNegativeSore throat−5/0Negative (55)Negative
  • *Variant, SARS-CoV-2 variant status was determined using S-Gene Target Failure, N501Y Mutation PCR and/or gene sequencing combined with epidemiological information (first alpha variant cases were detected 18 December in Finland).

  • †NA, not available.

  • ‡Wild-type, refers to Wuhan like non_VoC lineages.

  • RT-PCR, reverse transcriptase-polymerase chain reaction.